Notably, given that elevated serum FGF23 levels are directly associated with cardiovascular morbidity in patients with or without renal disease (54, 55), monitoring serum FGF23 levels may be helpful in patients with FHH to assess the risk of cardiovascular diseases. This evidence concerns the gene FGF23 and familial hypocalciuric hypercalcemia.